Filtered By:
Therapy: Endocrine Therapy
This page shows you your search results in order of date. This is page number 8.
Order by Relevance | Date
Total 2859 results found since Jan 2013.
Real-World Predictors of Severe Neutropenia Associated with Palbociclib and Endocrine Therapy for Metastatic Breast Cancer in Japanese Patients
Biol Pharm Bull. 2023;46(8):1105-1111. doi: 10.1248/bpb.b23-00187.ABSTRACTTherapy for patients of metastatic breast cancer based on palbociclib, a cyclin-dependent kinase 4/6 inhibitor, has been approved in Japan. However, the risk factors for palbociclib-induced severe neutropenia in Japanese patients are rarely reported. Hence, the present study is aimed to identify the risk factors for adverse events requiring palbociclib dose reduction or discontinuation, and to identify the factors necessary to identify a more stable strategy for treatment continuation. This retrospective cohort analysis included patients with advance...
Source: Biological and Pharmaceutical Bulletin - August 2, 2023 Category: Drugs & Pharmacology Authors: Shinya Takada Hideki Maeda Kengo Umehara Sayuri Kuwahara Mitsugu Yamamoto Nobumoto Tomioka Kenichi Watanabe Kozo Mino Source Type: research
Effects of aromatase inhibitor therapy on adiposity and cardiometabolic health in postmenopausal women: a controlled cohort extension study
CONCLUSIONS: While these findings provide reassurance that short-to-medium-term exposure to AI therapy is not associated with metabolically adverse changes when compared to controls, risk evolution should be less focused on the AI-associated-effect, and more on the general development of cardiovascular risk over time.PMID:37522858 | DOI:10.1530/EC-23-0076
Source: Atherosclerosis - July 31, 2023 Category: Cardiology Authors: Yee-Ming M Cheung Rudolf Hoermann Karen Van Damian Wu Jenny Healy Bella Halim Manjri Raval Maria McGill Ali Al-Fiadh Michael Chao Shane White Belinda Yeo Jeffrey D Zajac Mathis Grossmann Source Type: research
Identification of an Imidazopyridine-based Compound as an Oral Selective Estrogen Receptor Degrader for Breast Cancer Therapy
Cancer Res Commun. 2023 Jul 27;3(7):1378-1396. doi: 10.1158/2767-9764.CRC-23-0111. eCollection 2023 Jul.ABSTRACTThe pro-oncogenic activities of estrogen receptor alpha (ERα) drive breast cancer pathogenesis. Endocrine therapies that impair the production of estrogen or the action of the ERα are therefore used to prevent primary disease metastasis. Although recent successes with ERα degraders have been reported, there is still the need to develop further ERα antagonists with additional properties for breast cancer therapy. We have previously described a benzothiazole compound A4B17 that inhibits the proliferation of and...
Source: Cell Research - July 31, 2023 Category: Cytology Authors: Mengwu Pan Valeria Solozobova Nane C Kuznik Nicole Jung Simone Gr äßle Victor Gourain Yvonne M Heneka Christina A Cramer von Clausbruch Olaf Fuhr Ravi S N Munuganti Danilo Maddalo Christine Blattner Antje Neeb Adam Sharp Laura Cato Carsten Weiss Rinath Source Type: research
Fight Aging! Newsletter, July 31st 2023
In conclusion, an SBP level below 130 mmHg was found to be associated with longevity among older women. The longer SBP was controlled at a level between 110 and 130 mmHg, the higher the survival probability to age 90. Preventing age-related rises in SBP and increasing the time with controlled BP levels constitute important measures for achieving longevity.
« Back to Top
Source: Fight Aging! - July 30, 2023 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
ASO Visual Abstract: Neoadjuvant Chemotherapy and Endocrine Therapy for Older Patients with Estrogen Receptor Positive Breast Cancer-Comparison of Approaches
Ann Surg Oncol. 2023 Jul 30. doi: 10.1245/s10434-023-14010-4. Online ahead of print.NO ABSTRACTPMID:37516728 | DOI:10.1245/s10434-023-14010-4
Source: Ann Oncol - July 29, 2023 Category: Cancer & Oncology Authors: Krislyn N Miller Samantha M Thomas Sydney M Record Laura H Rosenberger Maggie L DiNome Gayle DiLalla Jeremy M Force E Shelley Hwang Jennifer K Plichta Source Type: research
Adjuvant Endocrine Therapy in Premenopausal Women With Hormone Receptor-Positive Early-Stage Breast Cancer: Risk Stratification in a Real-World Setting
CONCLUSION: In a real-world setting, treatment options for premenopausal patients who are candidates for HT and OFS should take risk status into account. Therefore, every effort should be made to maintain patient adherence to treatment in order to manage toxicities and improve outcomes.PMID:37507257 | DOI:10.1016/j.clbc.2023.06.013
Source: Clinical Genitourinary Cancer - July 28, 2023 Category: Cancer & Oncology Authors: Raffaella D'Onofrio Claudia Omarini Angela Toss Isabella Sperduti Federico Piacentini Monica Barbolini Laura Cortesi Elena Barbieri Elisa Pettorelli Chiara Chiavelli Massimo Dominici Luca Moscetti Source Type: research
Sarcopenia and toxicity-related discontinuation of endocrine therapy in women with early-stage hormone-receptor-positive breast cancer
Conclusion Among women with early-stage HR+ BC who receive adjuvant radiotherapy and ET, sarcopenia is associated with toxicity-related early discontinuation of aET. Further studies should validate these findings in women who did not receive adjuvant RT. These high-risk patients may be candidates for aggressive symptom management and/or alternative treatment strategies to improve outcomes.PMID:37506979 | DOI:10.1016/j.ijrobp.2023.07.018
Source: Health Physics - July 28, 2023 Category: Physics Authors: Anurag Saraf Ismail Tahir Bonnie Hu Anna-Sophia W Dietrich P Erik Tonnesen Gregory C Sharp Gayle Tillman Eric J Roeland Ryan D Nipp Amy Comander Jeffery Peppercorn Florian J Fintelmann Rachel B Jimenez Source Type: research
Adjuvant Endocrine Therapy in Premenopausal Women With Hormone Receptor-Positive Early-Stage Breast Cancer: Risk Stratification in a Real-World Setting
CONCLUSION: In a real-world setting, treatment options for premenopausal patients who are candidates for HT and OFS should take risk status into account. Therefore, every effort should be made to maintain patient adherence to treatment in order to manage toxicities and improve outcomes.PMID:37507257 | DOI:10.1016/j.clbc.2023.06.013
Source: Clinical Genitourinary Cancer - July 28, 2023 Category: Cancer & Oncology Authors: Raffaella D'Onofrio Claudia Omarini Angela Toss Isabella Sperduti Federico Piacentini Monica Barbolini Laura Cortesi Elena Barbieri Elisa Pettorelli Chiara Chiavelli Massimo Dominici Luca Moscetti Source Type: research
Optimization of an Information Leaflet to Influence Medication Beliefs in Women With Breast Cancer: A Randomized Factorial Experiment
CONCLUSIONS: The optimized leaflet did not contain enhanced AET side effect information. Factorial experiments are efficient and effective for refining the content of information leaflet interventions.PMID:37494669 | DOI:10.1093/abm/kaad037
Source: Annals of Behavioral Medicine - July 26, 2023 Category: Psychiatry & Psychology Authors: Sophie M C Green Louise H Hall David P French Nikki Rousseau Catherine Parbutt Rebecca Walwyn Samuel G Smith Source Type: research
Endocrine Therapy for Surgeons: Practical Pearls for Managing Menopausal, Bone Loss and Sexual Adverse Effects
Ann Surg Oncol. 2023 Jul 26. doi: 10.1245/s10434-023-13907-4. Online ahead of print.ABSTRACTBreast cancer patients are living longer than ever before and as such the population of breast cancer survivors continues to grow. Approximately 80% of breast cancers are hormone receptor-positive (HR+) and most patients will receive neoadjuvant or adjuvant estrogen blockade, referred to as endocrine therapy. Although endocrine therapy reduces HR+ breast cancer recurrence by 30-50%, significant adverse effects pose a threat to treatment adherence. These adverse effects include vasomotor symptoms, colloquially referred to as hot flas...
Source: Ann Oncol - July 26, 2023 Category: Cancer & Oncology Authors: Kristin Rojas Laura M Spring Liz O'Riordan Anna Weiss Source Type: research
